Streetbeat News

Stock Prices

DIS

FOX

FOXA

PARA

BofA Securities analyst Jessica Reif Ehrlich maintains a Buy rating on Fox Corp (NASDAQ:FOX) (NASDAQ:FOXA), raising the price target to $40 from $34, citing growth prospects and competitive valuation against Disney (NYSE:DIS) and Paramount Global (NASDAQ:PARA) (NASDAQ:PARAA). Ehrlich highlights Fox's positioning for earnings acceleration in fiscal 2025, driven by an improving advertising landscape, momentum at Tubi, and strength in Live News and Sports. Fox's valuation offers downside protection, trading at ~6x calendar 2025 EV/EBITDA, below peers. The analyst also raised fiscal 2024 and 2025 EBITDA and EPS forecasts.

Portfolio Pulse from Anusuya Lahiri

May 09, 2024 | 7:12 pm

GSAT

Globalstar's stock price has decreased following the release of their Q1 earnings report.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 7:07 pm

HIMS

Hims & Hers Health's shares are experiencing an upward trend following the announcement of their Q1 financial results, which surpassed expectations. The company also provided optimistic revenue guidance for Q2 and the full year 2024, contributing to the positive momentum.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 7:03 pm

WBD

Warner Bros. Discovery shares are trading higher, reversing earlier losses following worse-than-expected Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 7:02 pm

RIVN

Benzinga's options scanner revealed significant options activity on Rivian Automotive (NASDAQ:RIVN), indicating a mixed sentiment among big-money traders, with 59% bullish and 27% bearish. The activity focuses on a price range between $7.5 and $20.0. Notable trades include both puts and calls with varying sentiments and strike prices. Rivian's current stock price is $10.2, with a recent downgrade by Truist Securities to Hold and a price target of $10. Analysts have mixed opinions, with price targets ranging from $9 to $15. The next earnings report is due in 89 days.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 7:01 pm

SBUX

Starbucks shares are trading higher, potentially rebounding from the decline experienced after last week's weak Q2 earnings report.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 7:01 pm

VECO

Veeco Instruments (NASDAQ:VECO) has received mixed analyst ratings over the past three months, with 6 analysts offering evaluations. The sentiment has shifted positively, with the average 12-month price target rising to $39.67, up 12.28% from the previous $35.33. Analysts from firms including Goldman Sachs, Barclays, Needham, Citigroup, and Benchmark have raised their price targets, reflecting optimism about the company's financial performance and market position. Veeco Instruments, a company engaged in manufacturing thin-film process equipment, has shown a positive revenue trend with a growth rate of 13.09% and a notable net margin of 12.44%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 7:01 pm

TONUSD

Toncoin (CRYPTO: TON) has seen a significant increase in its price, rising 8.79% in the last 24 hours to $6.32, and a 21.0% gain over the past week from $5.13. The coin's all-time high is $7.63. Trading volume surged 97.0% over the week, with the circulating supply growing by 0.26% to over 3.47 billion. Toncoin's market cap ranks it #9 at $21.94 billion.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 7:00 pm

CTMX

CytomX Therapeutics Inc (NASDAQ:CTMX) released initial data from its CX-904 Phase 1a study, showing a favorable safety profile and confirmed anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. The study, which enrolled 35 patients, demonstrated measurable tumor reduction in eight patients, including two with pancreatic cancer showing confirmed partial responses. Despite the positive clinical data, CTMX shares dropped 46.1% to $2.259. Analysts from Wedbush upgraded CTMX to Outperform, raising the price target from $3 to $8, citing promising technology validation and clinical pipeline progression. However, H.C. Wainwright remains cautious, awaiting a broader dataset for pancreatic cancer due to historical clinical challenges in this subtype, maintaining a Neutral rating without a price target.

Portfolio Pulse from Vandana Singh

May 09, 2024 | 6:59 pm

AMD

AMZN

ARM

INTC

QCOM

Arm Holdings Plc (NASDAQ:ARM) stock traded lower after its fiscal 2025 guidance disappointed investors, projecting revenues and EPS below analyst consensus. Despite this, analysts remain optimistic about ARM's growth potential in AI and chip design, competing directly with Qualcomm, Intel, and AMD. Analysts from BofA Securities, Needham, Rosenblatt, Mizuho, Goldman Sachs, and JPMorgan have reiterated their ratings, with price targets ranging from $110 to $180, highlighting ARM's leverage in semiconductor IP market share and its potential in Cloud and Automotive sectors.

Portfolio Pulse from Anusuya Lahiri

May 09, 2024 | 6:53 pm